Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy.

Affiliation

Department of Medical and Surgical Sciences, Sant'Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. [Email]

Abstract

Real-life data of retention rate and persistence of adalimumab in inflammatory bowel disease are still limited.

Keywords

Adalimumab,Crohn’s disease,Persistence,Retention rate,Safety,Ulcerative colitis,